Carrot concentrated powder, preparation method thereof and application of carrot concentrated powder in preparation of products for preventing or adjunctively treating non-alcoholic fatty liver disease

Abstract

The invention discloses concentrated carrot powder, a preparation method thereof and application of the concentrated carrot powder in preparation of products for prevention or adjuvant therapy of non-alcoholic fatty liver, belongs to the technical field of food processing, and particularly relates to a preparation method of the concentrated carrot powder, which comprises the following steps: cleaning and peeling carrots, physically juicing, and then filtering to obtain normal carrot juice; and carrying out vacuum concentration to 1 / 5-1 / 3 of the original volume to obtain concentrated carrot juice, mixing the concentrated carrot juice with maltodextrin, Arabic gum and vitamin C to obtain a mixed solution, and carrying out homogenizing treatment and spray drying to obtain the concentrated carrot powder. The carrot concentrated powder provided by the invention can effectively prevent or assist in improving multiple pathological expressions such as abnormal weight increase, liver lipid deposition, serum lipid level abnormality and insulin resistance of NAFLD model mice induced by high fat diet, can assist in effectively intervening in the non-alcoholic fatty liver disease, and is wide in application prospect and easy to popularize. And a new solution is provided for preventing and managing the disease through a dietary approach.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of food processing, and particularly relates to carrot concentrate powder, a preparation method thereof, and application of the carrot concentrate powder in preparation of a product for preventing or adjuvant treating non-alcoholic fatty liver. BACKGROUND

[0002] Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world, and its disease spectrum covers simple hepatocyte steatosis to non-alcoholic steatohepatitis (NASH), and can further develop into liver fibrosis, liver cirrhosis and even hepatocellular carcinoma. The occurrence of the disease is closely related to obesity, insulin resistance, metabolic syndrome, etc. With the change of global lifestyle, the prevalence rate of the disease continues to rise, and it has become a serious public health problem. At present, there is still a lack of recognized specific drugs that can effectively reverse liver steatosis and inflammation in clinic. The mainstream treatment strategy focuses on lifestyle intervention, such as dietary adjustment and increased exercise, but its long-term compliance is poor, and the effect is limited. Therefore, it is of important practical significance and application value to develop safe and effective dietary intervention products or functional foods for preventing and adjuvant treating NAFLD.

[0003] Natural plants and their extracts are concerned in the prevention and treatment of metabolic diseases due to their multi-target and multi-pathway characteristics and high safety. As a common vegetable, carrot (Daucus carota L.) is rich in carotenoids such as β-carotene, α-carotene, lutein, and polyphenols, vitamins, dietary fiber and various minerals. Studies have shown that the active ingredients in carrot, especially carotenoids and polyphenols, have antioxidant, anti-inflammatory, lipid metabolism regulation and insulin sensitivity improvement activities. In theory, these characteristics make it have potential benefits in improving liver lipid accumulation, oxidative stress and low-grade inflammation.

[0004] At present, there are various carrot-related products on the market, such as fresh carrot juice, clarified carrot juice, carrot compound fruit and vegetable juice, etc. However, these traditional products have obvious limitations when applied to the dietary management of NAFLD, such as the concentration and stability of active ingredients. The concentration of active ingredients (such as carotenoids and polyphenols) in conventional carrot juice is relatively low, and a large amount of juice needs to be ingested to achieve potential health effects, which is not feasible. In addition, these components are easily degraded by light, heat and oxygen during processing and storage, resulting in unstable product efficacy. Existing carrot juice products are mostly developed as ordinary nutritional beverages, and their formulations and processes are not designed and optimized for regulating liver lipid metabolism, reducing liver oxidative damage and inflammation, and other core pathological links of NAFLD. Therefore, there is a lack of sufficient theoretical basis and efficacy targeting. Therefore, it is urgent to develop a carrot deep processing product with high concentration of active ingredients, high stability, good bioavailability, and a scientific and controllable preparation method, which can fully retain and enrich the ingredients beneficial to liver health. The application of such products to the preparation of products for preventing and / or adjuvant therapy of NAFLD can provide a novel, safe and convenient dietary intervention option for patients and high-risk groups, fill the current market gap, and have good development prospects and social and economic value. SUMMARY

[0005] To solve the above technical problems, the present application provides a carrot concentrate powder and its preparation method and application in the preparation of products for preventing or adjuvant therapy of non-alcoholic fatty liver disease. The carrot concentrate powder provided by the present application can effectively prevent or adjuvant improve the multiple pathological manifestations of abnormal body weight increase, liver lipid deposition, abnormal serum lipid level and insulin resistance in NAFLD model mice induced by high-fat diet, and can adjuvant effectively intervene non-alcoholic fatty liver disease, which has wide application prospect and provides a new solution for preventing and managing the disease through dietary approach.

[0006] To achieve the above-mentioned purpose, the present application provides a preparation method of carrot concentrate powder, comprising the following steps: 1) washing and peeling carrots, physically squeezing juice, then filtering to obtain carrot original juice; 2) reducing the pressure of the carrot original juice obtained in step 1) to 1 / 5~1 / 3 of the original volume to obtain concentrated carrot juice; 3) mixing the concentrated carrot juice obtained in step 2) with malt dextrin, gum arabic and vitamin C to obtain a mixed solution, homogenizing, spray drying to obtain carrot concentrate powder.

[0007] Preferably, the filtering in step 1) is to remove coarse fibers by using fine gauze.

[0008] Preferably, the vacuum degree of the reduced pressure concentration in step 2) is 0.009~0.05MPa, and the temperature of the reduced pressure concentration is 45~55℃. The reduced pressure concentration is aimed at removing part of the water to improve the subsequent drying efficiency, while avoiding long-time high-temperature damage to heat-sensitive ingredients.

[0009] Preferably, the ratio of the concentrated carrot juice, maltodextrin, gum arabic and vitamin C in step 3) is 600 mL: 16-26 g: 0.3-0.9 g: 2-4 g. The above specific ratio of additives is to build a stable embedding system. Maltodextrin acts as a drying aid to improve drying efficiency and prevent wall sticking. Gum arabic acts as an emulsion stabilizer and color protection agent, effectively retaining the flavor of carrots. Vitamin C provides an acidic environment and acts as an antioxidant to prevent oxidation and discoloration of active ingredients.

[0010] Preferably, the rotation speed of the homogenization treatment in step 3) is 14000-16000 rpm, the temperature of the homogenization treatment is 10-25℃, and the time of the homogenization treatment is 5-15 min. Homogenization treatment is to fully integrate and form a uniform and stable emulsion.

[0011] Preferably, the inlet air temperature of the spray drying in step 3) is 150-190℃, the outlet air temperature of the spray drying is 150-190℃, and the pump speed of the spray drying is 10%-20%. The soluble solids content of the carrot concentrate powder is 8%-13%.

[0012] The present application also provides the carrot concentrate powder prepared by the preparation method.

[0013] Preferably, the active ingredients in the carrot concentrate powder include organic acids and their derivatives, lipids and lipid molecules, and organic oxygen compounds.

[0014] The present application also provides the use of the carrot concentrate powder in the preparation of products for preventing and / or adjuvant therapy of non-alcoholic fatty liver.

[0015] Preferably, the product is a functional food.

[0016] Compared with the prior art, the present application has the following advantages and technical effects: The present application provides carrot concentrate powder, a preparation method thereof and application thereof in preparing products for preventing or assisting in treating non-alcoholic fatty liver, wherein about 200 mL of original juice can be obtained from 500 g of fresh carrot by using the preparation method, and 11.1 g of loose carrot concentrate powder with good fluidity and bright color can be finally prepared, and the carrot concentrate powder can be quickly reconstituted when used. The main substance groups and their relative abundance ratios of the carrot concentrate powder prepared by the present application are as follows: about 29.78% of organic acids and their derivatives, mainly including 7.31% of malic acid, 5.36% of D-phenylalanine, 3.21% of isoleucine, 2.29% of phenylalanine and 1.32% of L-arginine; about 27.18% of lipids and lipid molecules, mainly including 3.28% of linoleic acid and 3.12% of lysophosphatidylcholine; about 19.55% of organic oxygen compounds, mainly including 6.87% of sucrose, 3.95% of trehalose and 2.17% of myo-inositol galactoside; about 8.28% of organic heterocyclic compounds, and about 6.40% of organic nitrogen compounds. The specific metabolomics component characteristics of the carrot concentrate powder are determined by the specific preparation method of the present application, and the synergistic effect of multiple active ingredients constitutes the material basis for the carrot concentrate powder of the present application to prevent or assist in treating non-alcoholic fatty liver. The carrot concentrate powder prepared by the present application can effectively inhibit the excessive growth of NAFLD mice induced by high-fat diet, improve liver steatosis and inflammatory state, regulate serum lipid level and restore liver function, and at the same time, enhance the glucose tolerance and insulin sensitivity of the body, thereby providing experimental basis for the concentrated carrot juice as a potential drug for preventing and assisting in treating non-alcoholic fatty liver. BRIEF DESCRIPTION OF DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the drawings needed in the embodiments will be briefly introduced as follows. Obviously, the drawings in the following description are only some embodiments of the present application, and other drawings can be obtained by those skilled in the art without creative labor.

[0018] Figure 1 The preparation process flow chart of the carrot concentrate powder of the present application is shown in the figure. Figure 2 The non-targeted metabolomics analysis results of the carrot concentrate powder prepared in Example 1 are shown in the figure, wherein A is a chemical classification count column chart of main metabolites, B is a relative abundance distribution circular chart of each chemical classification metabolite, and C is a statistical chart of the top 5 characteristic compounds in the main categories. Figure 3Figure 1 is a weight change analysis of mice in each experimental group in Experimental Example 1 over a 14-week experimental period, wherein A is a photograph of each group of mice at 14 weeks, B is a weight change curve of each group of mice over 14 weeks, and C is a statistical analysis graph of the body weight of each group of mice at 14 weeks, wherein Control represents the blank control group, Model represents the model group, Positive represents the positive drug group, High-CJ represents the high-dose concentrated carrot juice intervention group, and Low-CJ represents the low-dose concentrated carrot juice intervention group. Figure 4 Figure 2 is a liver histopathological staining result of mice in each experimental group in Experimental Example 1, wherein A is a photograph of the liver tissue of mice, B is a H&E staining section and an oil red O staining section of the liver tissue, and Control represents the blank control group, Model represents the model group, Positive represents the positive drug group, High-CJ represents the high-dose concentrated carrot juice intervention group, and Low-CJ represents the low-dose concentrated carrot juice intervention group. Figure 5 Figure 3 is a serum lipid level analysis graph of mice in each experimental group in Experimental Example 1, wherein A is a low-density lipoprotein cholesterol level in plasma, B is a high-density lipoprotein cholesterol level in plasma, C is an aspartate aminotransferase activity in plasma, D is an alanine aminotransferase activity in plasma, E is a serum triglyceride level, and F is a total cholesterol level in serum, wherein Control represents the blank control group, Model represents the model group, Positive represents the positive drug group, High-CJ represents the high-dose concentrated carrot juice intervention group, and Low-CJ represents the low-dose concentrated carrot juice intervention group. Figure 6 ​​​​​​​Figures for analyzing the glucose metabolism function of mice in each experimental group in Experimental Example 1, wherein A is a graph of blood glucose change in the glucose tolerance experiment, B is a graph of the area under the blood glucose concentration-time curve, C is a graph of blood glucose change in the insulin tolerance experiment, D is a graph of the area under the insulin concentration-time curve, and Control represents the blank control group, Model represents the model group, Positive represents the positive drug group, High-CJ represents the high-dose concentrated carrot juice intervention group, Low-CJ represents the low-dose concentrated carrot juice intervention group, ”, ”, ” and ” represent significance analysis. DETAILED DESCRIPTION

[0019] The various illustrative embodiments of the present application will now be described in detail below. This description is not to be considered limiting in scope, but rather as merely descriptive of certain aspects, characteristics and embodiments of the present application.

[0020] It should be understood that the terms used in the present application merely describe particular embodiments and are not intended to limit the present application. In addition, for numerical ranges in the present application, it should be understood that each intermediate value between the upper limit and the lower limit of the range is specifically disclosed. Each smaller range within the larger range, as well as each intermediate value within the stated range, is also included in the present application. The upper and lower limits of these smaller ranges can be independently included or excluded from the range.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, preferred methods and materials are described. All publications mentioned in this specification are herein incorporated by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The citation of any reference in this specification is not intended as an admission that the reference is prior art, but rather that the reference is part of the state of the art.

[0022] Many modifications and variations of this application specification can be made in light of the above teachings without departing from the spirit or scope of the application. Other implementations of the application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. The specification and examples given are exemplary only.

[0023] As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "contains", "containing", or variations thereof, are intended to be open-ended terms that mean inclusion, but not limited to, the listed material or list of materials.

[0024] Example 1 1) Fresh carrots were washed and peeled, and then physically squeezed by a Philips juicer (model HR1871) to obtain carrot juice. The carrot juice was filtered by gauze to remove coarse fibers, and the soluble solid content of the carrot juice was measured to be 8% (Brix).

[0025] 2) The carrot juice was concentrated under reduced pressure to 1 / 4 of the original volume at a vacuum degree of 0.03 MPa and a temperature of 50°C to obtain concentrated carrot juice. The soluble solid content of the concentrated carrot juice was controlled to be 11% (Brix) at the end of the concentration.

[0026] 3) The concentrated carrot juice was mixed with maltodextrin, gum arabic and vitamin C at a ratio of 600 mL:21 g:0.6 g:3 g to obtain a mixed solution. The mixed solution was homogenized in a homogenizer (model: APV-200) at a speed of 15000 rpm and a temperature of 18°C for 10 min, and then pumped into a spray dryer (model: BUCHI B-290) at an inlet temperature of 160°C, an outlet temperature of 160°C and a pump speed of 15% to obtain carrot concentrate powder. In this embodiment, about 200 mL of original juice can be obtained from 500 g of fresh carrots, and finally 11.1 g of loose, flowable and bright carrot concentrate powder is obtained.

[0027] The flow chart of the preparation method of the carrot concentrate powder is shown in Figure 1 .

[0028] The prepared 11 g of carrot concentrate powder was dissolved in 200 mL of warm water and subjected to full-spectrum metabolomics analysis by ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) technology.

[0029] The results are shown in Figure 2 A, Figure 2 B and Figure 2As shown in FIG. 8, among the detected metabolites, according to the chemical classification, the main substance groups and their relative abundance ratios are as follows: organic acids and derivatives, accounting for about 29.78%; lipids and lipid-like molecules, accounting for about 27.18%; organic oxygen compounds, accounting for about 19.55%; and organic heterocyclic compounds (8.28%), organic nitrogen compounds (6.40%), etc. Further analysis of the top three categories with the highest abundance ratios shows that the top-ranking characteristic functional ingredients in each category include (data based on ion peak intensity relative abundance): organic acids and derivatives, mainly including malic acid (7.31%), D-phenylalanine (5.36%), isoleucine (3.21%), phenylalanine (2.29%), and L-arginine (1.32%); lipids and lipid-like molecules, mainly including linoleic acid (3.28%) and lysophosphatidylcholine substances (such as LysoPC 16:0, 3.12%); and organic oxygen compounds, mainly including sucrose (6.87%), trehalose (3.95%), and galactinol (2.17%). The specific metabolomic component characteristics of the carrot concentrate powder prepared in this embodiment are determined by the specific preparation method, and the synergistic effect of multiple active ingredients constitutes the material basis for preventing and adjuvant treating non-alcoholic fatty liver disease.

[0030] Example 2 1) Fresh carrots were washed and peeled, and then physically squeezed using a Philips juicer (model HR1871) to obtain carrot juice. The carrot juice was filtered through fine gauze to remove coarse fibers.

[0031] 2) The carrot juice was concentrated under reduced pressure to 1 / 3 of the original volume at a vacuum degree of 0.009 MPa and a temperature of 45°C to obtain concentrated carrot juice.

[0032] 3) The concentrated carrot juice was mixed with maltodextrin, gum arabic, and vitamin C at a ratio of 600 mL:16 g:0.3 g:2 g to obtain a mixture. The mixture was homogenized in a homogenizer (model: APV-200) at a speed of 14000 rpm and a temperature of 10°C for 15 min, and then pumped into a spray dryer (model: BUCHI B-290) at an inlet air temperature of 150°C, an outlet air temperature of 150°C, and a pump speed of 10% to obtain carrot concentrate powder.

[0033] Example 3 1) Fresh carrots were washed and peeled, and then squeezed by a Philips juicer (model: HR1871) to obtain carrot juice. The juice was filtered by a fine gauze to remove coarse fibers, and then the carrot juice was obtained.

[0034] 2) The carrot juice was concentrated under reduced pressure at 0.05 MPa and 55°C to 1 / 5 of the original volume, and then the concentrated carrot juice was obtained.

[0035] 3) The concentrated carrot juice was mixed with maltodextrin, gum arabic and vitamin C at a ratio of 600 mL: 26 g: 0.9 g: 4 g to obtain a mixed solution. The mixed solution was homogenized in a homogenizer (model: APV-200) at a speed of 16000 rpm and a temperature of 25°C for 5 minutes. The mixed solution was pumped into a spray dryer (model: BUCHI B-290) at an inlet temperature of 190°C, an outlet temperature of 190°C, and a pump speed of 20%, and then carrot concentrate powder was obtained.

[0036] Experimental Example 1 In this experiment, 5-6 week old male C57BL / 6 mice weighing 18-22 g were used. All mice were randomly divided into 5 groups after 1 week of adaptive feeding: a blank control group (Control group), a model group (Model group), a positive drug control group (Positive group), a high-dose carrot juice intervention group (High-CJ group), and a low-dose carrot juice intervention group (Low-CJ group). The blank control group was free to eat ordinary feed and drink water throughout the experiment; the model group, the positive drug control group, the high-dose carrot juice intervention group, and the low-dose carrot juice intervention group were fed with high-fat feed from the second week to the fourteenth week to establish a non-alcoholic fatty liver (NAFLD) model. At the same time, from the second week, each group was intervened as follows: the blank control group and the model group were given 0.2 mL of pure water by gavage every day; the positive drug control group was given simvastatin solution (10 mg / kg) by gavage; the high-dose carrot juice intervention group was given 4.6 g / kg of carrot concentrate powder dissolved in pure water; the low-dose carrot juice intervention group was given 2.3 g / kg of carrot concentrate powder dissolved in pure water, and the intervention lasted until the fourteenth week. According to the body surface area conversion coefficient of humans and mice (human / mouse ≈ 0.081), the recommended equivalent dose for humans (based on a body weight of 60 kg) was 11-22 g of carrot concentrate powder per day, which was dissolved in 200-400 mL of warm water to make carrot juice, and was taken orally once a day or in divided doses, and was recommended to be taken for at least 8 weeks.

[0037] Mouse weight changes were recorded weekly during the experiment. After the experiment, mice were euthanized, and liver tissue and serum samples were collected. Liver tissue was photographed, and tissue sections were prepared for H&E staining and Oil Red O staining to observe pathological changes such as hepatic steatosis, ballooning degeneration, and inflammatory cell infiltration. Serum lipid indicators, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and total cholesterol (TC), as well as liver function-related enzyme activities, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT), were measured. Further glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed to measure changes in blood glucose and insulin levels over time, and the area under the curve (AUC) was calculated to assess the mice's glucose metabolism function.

[0038] like Figure 3 As shown, Figure 3 As can be seen in Figure A, all mice in each group survived well throughout the 14-week experiment, and no unexpected deaths occurred. Figure 3 As shown in Figure B, after starting the high-fat diet in week 2, the weight gain of mice in the model group was significantly faster than that in the blank control group (P<0.0001), indicating that the non-alcoholic fatty liver disease (NAFLD) model was successfully established. In addition, at the start of the treatment intervention in week 2, the weight gain trend of mice in the high-dose carrot juice intervention group, low-dose carrot juice intervention group, and positive drug control group was slower than that in the model group. Among them, the weight control effect of the high-dose carrot juice intervention group was particularly significant (P<0.001), and the weight was close to that of mice in the positive drug control group. Figure 3 Further investigation by C confirmed that at week 14, the body weight of mice in both the high-dose carrot juice intervention group and the low-dose carrot juice intervention group was significantly lower than that in the model group (P<0.01), and showed a dose-dependent improvement.

[0039] like Figure 4 As shown, Figure 4 As can be seen in Figure A, the livers of mice in the model group were enlarged and yellowish-brown in color, exhibiting the typical macroscopic morphology of fatty liver. After intervention with high-dose carrot juice and low-dose carrot juice, the liver color and volume recovered to a state close to that of the blank control group. Figure 4 As shown in the B-stain, H&E staining revealed significant fatty vacuolation and ballooning degeneration in the hepatocytes of the model group, accompanied by inflammatory cell infiltration. After intervention with concentrated carrot juice, the morphology and structure of hepatocytes improved, and fatty degeneration and inflammatory infiltration were reduced. Oil Red O staining further confirmed that there was a large amount of lipid deposition in the liver of the model group. The lipid droplet area was significantly reduced in both the high-dose carrot juice intervention group and the high-dose carrot juice intervention group (P<0.001), indicating that concentrated carrot powder can effectively inhibit lipid accumulation in the liver.

[0040] like Figure 5As shown, compared with the blank control group, the serum low-density lipoprotein cholesterol (LDL-C) in the model group mice was significantly higher. Figure 5 (A) and triglycerides (TG) Figure 5 (E) and total cholesterol (TC) Figure 5 The levels of F1 and F2 were significantly increased (P<0.001), while high-density lipoprotein cholesterol (HDL-C) was significantly decreased. Figure 5 The level of B12 (B2) decreased; aspartate aminotransferase (AST) levels decreased. Figure 5 (C) and alanine aminotransferase (ALT, Figure 5 The activity of LDL-C was also significantly increased (P<0.0001), indicating liver function impairment. After intervention with concentrated carrot juice, the above-mentioned blood lipid indicators and liver enzyme activities were significantly reduced in both the high-dose carrot juice intervention group and the low-dose carrot juice intervention group (P<0.01). Among them, the high-dose carrot juice intervention group was more effective than the low-dose carrot juice intervention group in reducing LDL-C, TG, TC and ALT, and its effect was comparable to that of the positive drug group.

[0041] like Figure 6 As shown, in the oral glucose tolerance test (OGTT), the area under the blood glucose curve (AUC) of the model group mice was significantly greater than that of the blank control group (P<0.0001). Figure 6 (A) indicates impaired glucose tolerance; after high-dose carrot juice intervention and low-dose carrot juice intervention, the increase in blood glucose was significantly reduced, and the OGTT-AUC was also significantly decreased (P<0.01, Figure 6 (B) In the insulin tolerance test (ITT), the blood glucose level in the model group decreased slowly, and the ITT-AUC was significantly higher than that in the blank control group (P<0.0001). Figure 6 The presence of insulin resistance (C) was observed in the concentrated carrot juice intervention group; the blood glucose level decreased more rapidly and ITT-AUC was significantly lower (P<0.01). Figure 6 (D), with the high-dose carrot juice intervention group showing more significant improvement.

[0042] In conclusion, the intervention of concentrated carrot juice dissolved from carrot concentrate powder can effectively inhibit excessive weight gain in NAFLD mice induced by a high-fat diet, improve hepatic steatosis and inflammation, regulate serum lipid levels and restore liver function, while enhancing the body's glucose tolerance and insulin sensitivity. This provides experimental evidence for carrot concentrate powder as a potential drug for the prevention and adjuvant treatment of non-alcoholic fatty liver disease.

[0043] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for preparing carrot concentrate, characterized in that, Includes the following steps: 1) Wash and peel the carrots, juice them using physical methods, and then filter the juice to obtain the original carrot juice; 2) The carrot juice obtained in step 1) is concentrated under reduced pressure to 1 / 5 to 1 / 3 of its original volume to obtain concentrated carrot juice; 3) Mix the concentrated carrot juice obtained in step 2) with maltodextrin, gum arabic and vitamin C to obtain a mixture, homogenize it and spray dry it to obtain concentrated carrot powder.

2. The preparation method according to claim 1, characterized in that, The filtration described in step 1) involves using fine gauze to remove coarse fibers.

3. The preparation method according to claim 1, characterized in that, In step 2), the vacuum degree of the vacuum concentration is 0.009~0.05MPa, and the temperature of the vacuum concentration is 45~55℃.

4. The preparation method according to claim 1, characterized in that, The ratio of concentrated carrot juice to maltodextrin, gum arabic and vitamin C in step 3) is 600mL: 16~26g: 0.3~0.9g: 2~4g.

5. The preparation method according to claim 1, characterized in that, The homogenization process in step 3) is performed at a rotation speed of 14,000 to 16,000 rpm, at a temperature of 10 to 25°C, and for a time of 5 to 15 minutes.

6. The preparation method according to claim 1, characterized in that, In step 3), the inlet air temperature of the spray dryer is 150~190℃, the outlet air temperature of the spray dryer is 150~190℃, and the pump speed of the spray dryer is 10%~20%.

7. Carrot concentrate powder prepared by the preparation method according to any one of claims 1 to 6.

8. The carrot concentrate according to claim 7, characterized in that, The active ingredients in the carrot concentrate include organic acids and their derivatives, lipids and lipid molecules, and organic oxides.

9. The use of the carrot concentrate powder as described in claim 7 in the preparation of products for the prevention or adjunctive treatment of non-alcoholic fatty liver disease.

10. The application according to claim 9, characterized in that, The product is a functional food.

Images